News | May 07, 2025
AstraZeneca's enhertu improved pCR in early-stage breast cancer
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
AstraZeneca and Daiichi Sankyo’s Enhertu followed by THP showed an improved safety profile vs. standard of care
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
The countrywide initiative aims to spread awareness, educate the public & ensure that no one is left behind in the fight against respiratory diseases
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Education on Inhalation Therapy & Conducting Nationwide Awareness Camps, Alkem Breathe Initiative Addresses the Alarming Increase in Respiratory Diseases in India
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Subscribe To Our Newsletter & Stay Updated
